New Asia Expansion For BioNTech As It Builds On Global Success
Singapore Wins Out
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.
You may also be interested in...
As Singapore aims for growth in its biopharma manufacturing capability, three key players in the pharmaceutical industry announced plans to join a newly-formed public-private consortium designed to foster innovation in the production of vaccines and biologics.
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.